Medication Beliefs Affect Uptake of Preventive Tx for Breast Cancer
Uptake of preventive therapy low among those with strong concerns about tamoxifen, meds in general (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 14, 2018 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pharmacy, Journal, Source Type: news

Medication Beliefs Affect Uptake of Preventive Tx for Breast Cancer
FRIDAY, Dec. 14, 2018 -- Beliefs about medication are associated with uptake of tamoxifen as a preventive therapy among women at increased risk for breast cancer, according to a study published online Dec. 2 in Clinical Breast Cancer. Rachael Jane... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 14, 2018 Category: Pharmaceuticals Source Type: news

Are male doctors too complacent about the cancer pill many women say is ruining their lives?  
Tamoxifen is a daily pill taken by about 550,000 British breast cancer survivors. It can slash their risk of recurrence after treatment by up to 45 per cent. (Source: the Mail online | Health)
Source: the Mail online | Health - December 10, 2018 Category: Consumer Health News Source Type: news

Go Low With Tamoxifen for DCIS Go Low With Tamoxifen for DCIS
In a potentially practice-changing result, use of a 5-mg daily dose of tamoxifen for patients with ductal carcinoma in situ (DCIS) prevented new and recurrent breast cancer events in comparison with placebo.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 7, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Tamoxifen at a Lower Dose Might Still Prevent Breast Cancer's Return
Title: Tamoxifen at a Lower Dose Might Still Prevent Breast Cancer's ReturnCategory: Health NewsCreated: 12/6/2018 12:00:00 AMLast Editorial Review: 12/7/2018 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - December 7, 2018 Category: Cancer & Oncology Source Type: news

Low-Dose Tamoxifen Feasible Option in Breast Cancer
(MedPage Today) -- Women appear to prevent recurrence in early stage cancers with 5 mg dosing (Source: MedPage Today Surgery)
Source: MedPage Today Surgery - December 6, 2018 Category: Surgery Source Type: news

Can Low-Dose Tamoxifen Prevent Recurrences With Reduced Toxicity?
The TAM01 trial looked at whether a 5-mg/day dose of tamoxifen was effective in patients with breast intraepithelial neoplasia, or if the 20-mg/day dose was still the best option. (Source: CancerNetwork)
Source: CancerNetwork - December 6, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Lower-Dose Tamoxifen Works As Well As High-Dose
New research shows that a lower dose of the hormone therapy Tamoxifen is as effective as the higher dose treatment in helping to prevent breast cancer from returning and guarding against new cancers in women who had high-risk breast tissue. (Source: WebMD Health)
Source: WebMD Health - December 6, 2018 Category: Consumer Health News Source Type: news

Tamoxifen at a Lower Dose Might Still Prevent Breast Cancer ’ s Return
(Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 6, 2018 Category: Cancer & Oncology Tags: Endocrinology, Gynecology, Nursing, Oncology, Pharmacy, News, Source Type: news

Tamoxifen at a Lower Dose Might Still Prevent Breast Cancer's Return
THURSDAY, Dec. 6, 2018 -- Tamoxifen is considered a vital weapon in the fight against breast cancer, but many women who have to take the drug struggle with its significant side effects. Now, new research shows that a lower dose of the hormone... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 6, 2018 Category: General Medicine Source Type: news

SABCS: Low-Dose Tamoxifen Cuts Risk for Breast Dz
THURSDAY, Dec. 6, 2018 -- Tamoxifen at a dose of 5 mg/day is associated with a reduced risk for recurrence for women with hormone-sensitive breast intraepithelial neoplasia, according to a study presented at the annual San Antonio Breast Cancer... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 6, 2018 Category: Pharmaceuticals Source Type: news

Low-dose tamoxifen reduced recurrence and new disease for patients with DCIS, LCIS, and ADH
(American Association for Cancer Research) Treatment with a low dose of tamoxifen (5 mg per day) halved the risk of disease recurrence and new disease for women who had been treated with surgery following a diagnosis of breast intraepithelial neoplasia compared with placebo, and it did not cause more serious adverse events, according to data from the randomized, phase III TAM-01 clinical trial presented at the 2018 San Antonio Breast Cancer Symposium. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 6, 2018 Category: Cancer & Oncology Source Type: news

Tamoxifen at a Lower Dose Might Still Prevent Breast Cancer's Return
(Source: Cancercompass News: Breast Cancer)
Source: Cancercompass News: Breast Cancer - December 6, 2018 Category: Cancer & Oncology Source Type: news

Tamoxifen at a Lower Dose Might Still Prevent Breast Cancer's Return
(Source: Cancercompass News: Other Cancer)
Source: Cancercompass News: Other Cancer - December 6, 2018 Category: Cancer & Oncology Source Type: news

Adding Metformin to Tamoxifen to Protect the Endometrium Adding Metformin to Tamoxifen to Protect the Endometrium
Might the addition of metformin help mitigate the endometrial effects of tamoxifen therapy?Clinical Endocrinology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 3, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

A molecule for fighting muscular paralysis
(Universit é de Gen è ve) Myotubular myopathy is a severe genetic disease that leads to muscle paralysis. Although no treatment currently exists, researchers from the UNIGE-with the University of Strasbourg,- have identified a molecule that not only greatly reduces the progression of the disease but also boosts life expectancy in animal models by a factor of seven. Since the molecule -- known as tamoxifen -- is already used for breast cancer, the researchers hope to soon set up a clinical trial. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 19, 2018 Category: International Medicine & Public Health Source Type: news

This Combo Improves Outcomes Over Tamoxifen in Early Breast Cancer
New drug combo offers improved disease-free survival in patients with hormone receptor (HR)-positive early breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - November 7, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Zoledronic acid improves disease-free survival in premenopausal HR+ early breast cancer
(European Society for Medical Oncology) Adjuvant treatment with the bone sparing drug zoledronic acid plus hormonal therapy with the aromatase inhibitor letrozole significantly increases disease-free survival compared to tamoxifen in premenopausal women with hormone receptor positive (HR+) early breast cancer, according to results reported at ESMO 2018 Congress in Munich. It is the first study to assess this specific combination in premenopausal breast cancer and adds to previous observations with zoledronic acid and anastrozole in premenopausal women receiving ovarian suppression. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 22, 2018 Category: Cancer & Oncology Source Type: news

RT Add-On Boosts Outcomes in'Low-Risk' DCIS Breast Ca
(MedPage Today) -- Highest benefit seen in patients who also used tamoxifen (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 22, 2018 Category: Hematology Source Type: news

Recognizing Nonadherence to Tamoxifen in Early Breast Cancer Patients
In premenopausal patients with early breast cancer, approximately one-sixth are not adequately adherent to adjuvant endocrine therapy. (Source: CancerNetwork)
Source: CancerNetwork - October 19, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

One in six premenopausal early breast cancer patients do not adhere to hormonal therapy
(European Society for Medical Oncology) Nearly one in six premenopausal women being treated for early stage breast cancer do not adhere adequately to tamoxifen therapy after one year of treatment, potentially putting themselves at increased risk of recurrence and reduced survival, a French prospective study reports at ESMO 2018. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 18, 2018 Category: Cancer & Oncology Source Type: news

Cancer drug and antidepressants provide clues for treating brain-eating amoeba infections
(University of California - San Diego) Researchers at Skaggs School of Pharmacy and Pharmaceutical Sciences at University of California San Diego have now identified three new molecular drug targets in Naegleria fowleri and a number of drugs that are able to inhibit the amoeba's growth in a laboratory dish. Several of these drugs are already approved by the US Food and Drug Administration for other uses, such as antifungal agents, the breast cancer drug tamoxifen and antidepressant Prozac. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - September 13, 2018 Category: Infectious Diseases Source Type: news

Soltamox (Tamoxifen Citrate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 15, 2018 Category: Drugs & Pharmacology Source Type: news

Extended Tamoxifen May Double Endometrial Cancer Risk
(MedPage Today) -- But observed malignancies were detected early and carried low mortality risk (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - July 10, 2018 Category: Hematology Source Type: news

Breast-cancer drug taken by thousands of women doubles the risk of womb cancer
Researchers from St Vincent's Hospital Group, Dublin, found that taking tamoxifen for 10 years rather than five raises the risk of endometrial cancer from 1.5 per cent to 3.5 per cent. (Source: the Mail online | Health)
Source: the Mail online | Health - July 5, 2018 Category: Consumer Health News Source Type: news

Extended tamoxifen therapy may increase risk of endometrial cancer
(Wiley) There is clear evidence that extended adjuvant tamoxifen therapy for 10 years reduces local recurrence and improves breast cancer-free survival in women with oestrogen receptor-positive breast cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 5, 2018 Category: Cancer & Oncology Source Type: news

DNA Analysis in Early Breast Ca Reveals Markers of Recurrence
(MedPage Today) -- And PIK3CA mutations tied to letrozole benefit over tamoxifen (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 15, 2018 Category: Hematology Source Type: news

ASCO: Ovarian Suppression & #43; Tamoxifen Ups Breast CA Survival
TUESDAY, June 5, 2018 -- The addition of ovarian suppression to tamoxifen is associated with increased survival versus tamoxifen alone among premenopausal women with breast cancer, according to a study published online June 4 in the New England... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 5, 2018 Category: Pharmaceuticals Source Type: news

Thousands of breast cancer patients may be SPARED from chemotherapy
A landmark study in New York has found that a significant proportion of women with the disease need only a daily pill – such as tamoxifen – to stop their cancer returning after surgery. (Source: the Mail online | Health)
Source: the Mail online | Health - June 4, 2018 Category: Consumer Health News Source Type: news

5,000 British breast cancer patients per year could be spared chemotherapy by taking a daily pill
A landmark study in New York has found that a significant proportion of women with the disease need only a daily pill – such as tamoxifen – to stop their cancer returning after surgery. (Source: the Mail online | Health)
Source: the Mail online | Health - June 4, 2018 Category: Consumer Health News Source Type: news

Good News for Women With Breast Cancer: Many Don ’ t Need Chemo
Many women with early-stage forms of the disease can forego chemo, based on a test that measures the activity of genes involved in breast cancer recurrence. (Source: NYT Health)
Source: NYT Health - June 3, 2018 Category: Consumer Health News Authors: DENISE GRADY Tags: Breast Cancer Chemotherapy Tumors Hormones Tamoxifen (Drug) American Society of Clinical Oncology Genomic Health Inc Tests (Medical) Source Type: news

NICE guidance on tamoxifen prescribing has slow uptake
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - May 1, 2018 Category: Drugs & Pharmacology Source Type: news

Breast Cancer Risk and Tamoxifen Use
Only 1 in 7 Women at Risk for Breast Cancer Take Tamoxifen (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - April 30, 2018 Category: General Medicine Source Type: news

Only 1 in 7 Women at Risk for Breast Cancer Take Tamoxifen Only 1 in 7 Women at Risk for Breast Cancer Take Tamoxifen
A small study in the UK has found 6 of 7 women with a family history of breast cancer opted out of taking tamoxifen as a preventive measure.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 27, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

One in seven women taking pills which help prevent breast cancer
Only one in seven who are at high risk of breast cancer are taking Tamoxifen to reduce their chances of getting the disease, a study found. (Source: the Mail online | Health)
Source: the Mail online | Health - April 24, 2018 Category: Consumer Health News Source Type: news

Six in 7 women at high risk of breast cancer shun tamoxifen as a preventative measure
(Cancer Research UK) Six in seven women with a family history of breast cancer opt out of taking tamoxifen as a preventative measure, according to a study funded by Cancer Research UK and published in Breast Cancer Research and Treatment today. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 23, 2018 Category: Cancer & Oncology Source Type: news

Science Saturday: Z-Endoxifen emerges as potential breast cancer treatment
Summary Results of a phase I study in women showed that the treatment was safe and reduced tumors. Z-endoxifen, a potent derivative of the drug?tamoxifen, could be a new treatment for the most common form of breast cancer in women with metastatic disease. This finding was reported from a clinical trial conducted by researchers at [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - April 21, 2018 Category: Databases & Libraries Source Type: news

Tamoxifen and raloxifene slow down the progression of muscular dystrophy
(Elsevier) Steroids are currently the only available treatment to reduce the repetitive cycles of inflammation and disease progression associated with functional deterioration in patients with muscular dystrophy (MD). A study reported in The American Journal of Pathology showed that a new treatment approach using the selective estrogen receptor modulators (SERMs) tamoxifen and raloxifene significantly improved cardiac, respiratory, and skeletal muscle functions and increased bone density in both male and female mice with the same gene defects as a subset of patients with MD. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - March 20, 2018 Category: Biology Source Type: news

New international practice guidelines for tamoxifen treatment based on CYP2D6 genotype
(Mayo Clinic) An international group of clinicians and scientists representing the Clinical Pharmacogenetics Implementation Consortium (CPIC) published the first-ever clinical practice guideline for using CYP2D6 genotype to guide tamoxifen therapy in Clinical Pharmacology and Therapeutics. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 1, 2018 Category: Cancer & Oncology Source Type: news

Medical News Today: Can weight gain be caused by tamoxifen?
A look at the link between tamoxifen and weight gain. Included is detail on why weight gain can occur in breast cancer treatment, and other side effects. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 22, 2018 Category: Consumer Health News Tags: Breast Cancer Source Type: news

Novartis Kisqali ® received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2- advanced breast cancer
Novartis today announced Kisqali® (ribociclib) received US Food and Drug Administration (FDA) Breakthrough Therapy designation for initial endocrine-based treatment of pre- or perimenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer in combination with tamoxifen or an aromatase inhibitor. (Source: World Pharma News)
Source: World Pharma News - January 3, 2018 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

JACQUIE BELTRAO on her tamoxifen living hell
Tamoixifen might be a lifesaver for breast cancer patients, but it's irritating side effects, such as late night hot flushes, are absolutely awful, writes Sky News' JACQUIE BELTRAO. (Source: the Mail online | Health)
Source: the Mail online | Health - December 17, 2017 Category: Consumer Health News Source Type: news

Breast cancer can return 20 years after first diagnosis
The disease can ‘lie dormant’ for years, reappearing long after patients get all-clear, say Oxford University researchers. Women may be told to continue drugs like tamoxifen for longer. (Source: the Mail online | Health)
Source: the Mail online | Health - November 8, 2017 Category: Consumer Health News Source Type: news

Z-endoxifen shows promise as new treatment for common breast cancer type
(Mayo Clinic) ROCHESTER, Minn. - Z-endoxifen, a potent derivative of the drug tamoxifen, could itself be a new treatment for the most common form of breast cancer in women with metastatic disease. This finding was reported from a clinical trial conducted by researchers at Mayo Clinic and the National Cancer Institute, and published in the Journal of Clinical Oncology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 30, 2017 Category: International Medicine & Public Health Source Type: news

Z-endoxifen shows promise as new treatment for common breast cancer type
  ROCHESTER, Minn. ??Z-endoxifen, a potent derivative of the drug tamoxifen, could itself be a new treatment for the most common form of breast cancer in women with metastatic disease. This finding was reported from a clinical trial conducted by researchers at Mayo Clinic and the National Cancer Institute, and published in the Journal of [...] (Source: Mayo Clinic Minnesota News)
Source: Mayo Clinic Minnesota News - August 30, 2017 Category: Hospital Management Source Type: news

Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer
This video highlights trials studying the long-term impact of adjuvant tamoxifen and aromatase inhibitors for the treatment of patients with postmenopausal breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - August 25, 2017 Category: Cancer & Oncology Authors: Prudence A. Francis, MD Tags: Videos Breast Cancer Source Type: news

Breast cancer wonder drug boosts IVF hopes
A British clinic is pioneering the use of tamoxifen - typically given to patients who have undergone breast cancer surgery - to help women aged over 40 who have a limited number of eggs. (Source: the Mail online | Health)
Source: the Mail online | Health - August 13, 2017 Category: Consumer Health News Source Type: news

Gene Score for Recurrence Risk in ER-Positive Breast Cancer Gene Score for Recurrence Risk in ER-Positive Breast Cancer
Can this gene recurrence score help determine which patients with ER-positive breast cancer are good candidates for radiotherapy after adjuvant chemotherapy plus tamoxifen?Journal of the National Cancer Institute (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 20, 2017 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

RCT: Menopause Symptoms Mistaken for Tamoxifen Side Effects RCT: Menopause Symptoms Mistaken for Tamoxifen Side Effects
Many women who use tamoxifen as a chemopreventive agent experience symptoms that are assumed to be drug related, but they may just be naturally occurring symptoms related to menopause.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 6, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news